Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H18ClN3O3 |
| Molecular Weight | 371.818 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(=O)OC1N=C(C2=CC=CC=C2)C3=CC(Cl)=CC=C3N(C)C1=O
InChI
InChIKey=PXBVEXGRHZFEOF-UHFFFAOYSA-N
InChI=1S/C19H18ClN3O3/c1-22(2)19(25)26-17-18(24)23(3)15-10-9-13(20)11-14(15)16(21-17)12-7-5-4-6-8-12/h4-11,17H,1-3H3
| Molecular Formula | C19H18ClN3O3 |
| Molecular Weight | 371.818 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Camazepam is a benzodiazepine psychoactive drug, marketed under the brand names Albego, Limpidon and Paxor. It is the dimethyl carbamate ester of temazepam, a metabolite of diazepam. While it possesses anxiolytic, anticonvulsant, skeletal muscle relaxant and hypnotic properties it differs from other benzodiazepines in that its anxiolytic properties are particularly prominent but has comparatively limited anticonvulsant, hypnotic and skeletal muscle relaxant properties. Changes in sleep with camazepam were minimal. However, non-anxious subjects reported being more relaxed the next day. Camazepam may cause skin disorders.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Development and validation of an EI-GC-MS method for the determination of benzodiazepine drugs and their metabolites in blood: applications in clinical and forensic toxicology. | 2010-08-01 |
|
| Screening, library-assisted identification and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem and zopiclone in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. | 2004-08 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6120717
10, 20 and 40 mg overnight
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:44:54 GMT 2025
by
admin
on
Mon Mar 31 18:44:54 GMT 2025
|
| Record UNII |
HZ3XRH03C3
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DEA NO. |
2749
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
||
|
WHO-ATC |
N05BA15
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
||
|
NCI_THESAURUS |
C1012
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
||
|
WHO-VATC |
QN05BA15
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
469
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
HZ3XRH03C3
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
3500
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
SUB06061MIG
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
100000081596
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
CAMAZEPAM
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
DB01489
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
DTXSID50865803
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
36104-80-0
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
37367
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
252-866-6
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
C98123
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
m2997
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | Merck Index | ||
|
C084596
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY | |||
|
CHEMBL1095282
Created by
admin on Mon Mar 31 18:44:54 GMT 2025 , Edited by admin on Mon Mar 31 18:44:54 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |